search
Back to results

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CIN-107
Matching Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring pharmacokinetics (PK), metabolism, baxdrostat

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy subjects between the ages of 18 and 55 years, inclusive, in good health based on medical and psychiatric history, physical examination, ECG, orthostatic vital signs, and routine laboratory tests (blood chemistry, hematology, coagulation, and urinalysis).
  2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive.
  3. Nonsmokers who have not used nicotine-containing products for at least 6 months prior to the Screening Visit.

Exclusion Criteria:

  1. Actively participating in an experimental therapy study; received experimental therapy with a small molecule within 30 days of Day 1, or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of Day 1, or 5 half-lives, whichever is longer.
  2. A personal or family history of long QT syndrome, Torsades de Pointes, or other complex ventricular arrhythmias, or family history of sudden death.
  3. History of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, or atrial fibrillation.
  4. Prolonged QTcF (>450 msec) based on the average of triplicate ECGs.
  5. Seated blood pressure higher than 150/90 mmHg or lower than 90/50 mmHg.
  6. Resting heart rate higher than 100 bpm or lower than 50 bpm , sinus node dysfunction, or clinically significant heart block.
  7. Temperature (T) greater than 37.6o C (99.68o F, measured orally), and respiration rate less than 12 and greater than 20 breaths/minute.
  8. Postural tachycardia (ie >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic blood pressure (SBP) of ≥20 mm Hg or DBP of ≥ 10 mm Hg when a person assumes a standing position).
  9. Serum potassium > upper limit of normal of the reference range (ULN) and serum sodium < lower limit of normal of the reference range (LLN).
  10. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values > 1.2 ULN.
  11. Positive for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody, or Hepatitis B surface antigen (HBsAg).
  12. A known history of porphyria, myopathy, or an active liver disease.
  13. Positive drug or alcohol test result or a history of alcoholism or drug abuse within 2 years prior to the first dose of study drug as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition: DSM-IV.
  14. Typical consumption of ≥14 alcoholic drinks weekly.
  15. Surgical procedures within 4 weeks of check-in or planned elective surgery during the study period.
  16. Currently undergoing treatment with weight loss medication or prior weight loss surgery (eg, gastric bypass surgery).
  17. Pregnant, breastfeeding, or planning to become pregnant during the study.

Sites / Locations

  • Medpace Clinical Pharmacology Unit

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Cohort 1: 2.5 mg CIN-107

Cohort 2: 5.0 mg CIN-107

Cohort 3: 1.5 mg CIN-107

Cohort 4: 2.5 mg CIN-107

Cohort 5: 0.5 mg CIN-107

Cohort 1: 2.5 mg matching placebo

Cohort 2: 5.0 mg matching placebo

Cohort 3: 1.5 mg matching placebo

Cohort 4: 2.5 mg matching placebo

Cohort 5: 0.5 mg matching placebo

Arm Description

Subjects on a low salt diet

Subjects on a low salt diet

Subjects on a normal salt diet

Subjects on a normal salt diet

Subjects on a normal salt diet

Subjects on a low salt diet

Subjects on a low salt diet

Subjects on a normal salt diet

Subjects on a normal salt diet

Subjects on a normal salt diet

Outcomes

Primary Outcome Measures

Maximum plasma concentration (Cmax)
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.
Time to maximum plasma concentration (Tmax)
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.
Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last])
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Area under the curve from time 0 to infinity
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Area under the curve over a dosing interval (tau)
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Area under the plasma concentration-time curve (AUC) from time 0 to 24 hours
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first dose of CIN-107, as the data permit.
Percent of AUC extrapolated
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Terminal phase elimination half-life
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Apparent plasma clearance
This PK parameter will be determined for CIN-107 using plasma concentration data.
Apparent volume of distribution
This PK parameter will be determined for CIN-107 using plasma concentration data.
The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae)
This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)
Renal clearance (CLR Calculated as Ae/AUC) of CIN-107 and CIN-107-M
This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)
Fraction of the dose excreted renally (fe)
This PK parameter will be calculated using the urine concentrations of CIN-107
Number of patients experiencing adverse events (AEs)
Number of patients experiencing adverse drug reactions
Number of patients experiencing serious adverse events (SAEs)
Plasma concentration of aldosterone
Plasma renin activity
Plasma concentration of cortisol (free and total)
Plasma concentration of ACTH (Adrenocorticotropic hormone)

Secondary Outcome Measures

Full Information

First Posted
August 12, 2022
Last Updated
August 9, 2023
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT05500820
Brief Title
Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects
Official Title
A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CIN-107 Following Multiple Oral Doses in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
December 19, 2019 (Actual)
Primary Completion Date
April 3, 2020 (Actual)
Study Completion Date
April 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
pharmacokinetics (PK), metabolism, baxdrostat

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
56 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: 2.5 mg CIN-107
Arm Type
Experimental
Arm Description
Subjects on a low salt diet
Arm Title
Cohort 2: 5.0 mg CIN-107
Arm Type
Experimental
Arm Description
Subjects on a low salt diet
Arm Title
Cohort 3: 1.5 mg CIN-107
Arm Type
Experimental
Arm Description
Subjects on a normal salt diet
Arm Title
Cohort 4: 2.5 mg CIN-107
Arm Type
Experimental
Arm Description
Subjects on a normal salt diet
Arm Title
Cohort 5: 0.5 mg CIN-107
Arm Type
Experimental
Arm Description
Subjects on a normal salt diet
Arm Title
Cohort 1: 2.5 mg matching placebo
Arm Type
Placebo Comparator
Arm Description
Subjects on a low salt diet
Arm Title
Cohort 2: 5.0 mg matching placebo
Arm Type
Placebo Comparator
Arm Description
Subjects on a low salt diet
Arm Title
Cohort 3: 1.5 mg matching placebo
Arm Type
Placebo Comparator
Arm Description
Subjects on a normal salt diet
Arm Title
Cohort 4: 2.5 mg matching placebo
Arm Type
Placebo Comparator
Arm Description
Subjects on a normal salt diet
Arm Title
Cohort 5: 0.5 mg matching placebo
Arm Type
Placebo Comparator
Arm Description
Subjects on a normal salt diet
Intervention Type
Drug
Intervention Name(s)
CIN-107
Other Intervention Name(s)
baxdrostat
Intervention Description
A repeat oral dose of CIN-107 once daily for 10 days.
Intervention Type
Drug
Intervention Name(s)
Matching Placebo
Intervention Description
A repeat oral dose of matching placebo once daily for 10 days.
Primary Outcome Measure Information:
Title
Maximum plasma concentration (Cmax)
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Time to maximum plasma concentration (Tmax)
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first and last doses of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Area under the curve from time 0 to the time of last quantifiable plasma concentration (AUC[0-last])
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Area under the curve from time 0 to infinity
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Area under the curve over a dosing interval (tau)
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Area under the plasma concentration-time curve (AUC) from time 0 to 24 hours
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data and following the first dose of CIN-107, as the data permit.
Time Frame
up to Day 2
Title
Percent of AUC extrapolated
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Terminal phase elimination half-life
Description
This PK parameter will be determined for CIN-107, its primary metabolite (CIN-107-M), and any other measured metabolites using plasma concentration data following the final dose of CIN-107, as the data permit.
Time Frame
up to Day 15
Title
Apparent plasma clearance
Description
This PK parameter will be determined for CIN-107 using plasma concentration data.
Time Frame
up to Day 15
Title
Apparent volume of distribution
Description
This PK parameter will be determined for CIN-107 using plasma concentration data.
Time Frame
Up to Day 15
Title
The cumulative amount of CIN-107 and CIN-107-M excreted in the urine (Ae)
Description
This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)
Time Frame
up to Day 15
Title
Renal clearance (CLR Calculated as Ae/AUC) of CIN-107 and CIN-107-M
Description
This PK parameter will be calculated using the urine concentrations of CIN-107 and its primary metabolite (CIN-107-M)
Time Frame
up to Day 15
Title
Fraction of the dose excreted renally (fe)
Description
This PK parameter will be calculated using the urine concentrations of CIN-107
Time Frame
up to Day 15
Title
Number of patients experiencing adverse events (AEs)
Time Frame
up to Day 15
Title
Number of patients experiencing adverse drug reactions
Time Frame
up to Day 15
Title
Number of patients experiencing serious adverse events (SAEs)
Time Frame
up to Day 15
Title
Plasma concentration of aldosterone
Time Frame
up to Day 15
Title
Plasma renin activity
Time Frame
up to Day 15
Title
Plasma concentration of cortisol (free and total)
Time Frame
up to Day 15
Title
Plasma concentration of ACTH (Adrenocorticotropic hormone)
Time Frame
up to Day 15

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subjects between the ages of 18 and 55 years, inclusive, in good health based on medical and psychiatric history, physical examination, ECG, orthostatic vital signs, and routine laboratory tests (blood chemistry, hematology, coagulation, and urinalysis). Body mass index (BMI) between 18 and 30 kg/m2, inclusive. Nonsmokers who have not used nicotine-containing products for at least 6 months prior to the Screening Visit. Exclusion Criteria: Actively participating in an experimental therapy study; received experimental therapy with a small molecule within 30 days of Day 1, or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of Day 1, or 5 half-lives, whichever is longer. A personal or family history of long QT syndrome, Torsades de Pointes, or other complex ventricular arrhythmias, or family history of sudden death. History of, or current, clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, or atrial fibrillation. Prolonged QTcF (>450 msec) based on the average of triplicate ECGs. Seated blood pressure higher than 150/90 mmHg or lower than 90/50 mmHg. Resting heart rate higher than 100 bpm or lower than 50 bpm , sinus node dysfunction, or clinically significant heart block. Temperature (T) greater than 37.6o C (99.68o F, measured orally), and respiration rate less than 12 and greater than 20 breaths/minute. Postural tachycardia (ie >30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic blood pressure (SBP) of ≥20 mm Hg or DBP of ≥ 10 mm Hg when a person assumes a standing position). Serum potassium > upper limit of normal of the reference range (ULN) and serum sodium < lower limit of normal of the reference range (LLN). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values > 1.2 ULN. Positive for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody, or Hepatitis B surface antigen (HBsAg). A known history of porphyria, myopathy, or an active liver disease. Positive drug or alcohol test result or a history of alcoholism or drug abuse within 2 years prior to the first dose of study drug as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition: DSM-IV. Typical consumption of ≥14 alcoholic drinks weekly. Surgical procedures within 4 weeks of check-in or planned elective surgery during the study period. Currently undergoing treatment with weight loss medication or prior weight loss surgery (eg, gastric bypass surgery). Pregnant, breastfeeding, or planning to become pregnant during the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leela Vrishabhendra, MD
Organizational Affiliation
Medpace Clinical Pharmacology Unit
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medpace Clinical Pharmacology Unit
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing URL
https://vivli.org/
Citations:
PubMed Identifier
36266539
Citation
Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20.
Results Reference
background
Links:
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=CIN-107-111&attachmentIdentifier=5ae8edfe-848e-4a91-ad8a-ff0a5e360aae&fileName=cin-107-111-report-synopsis_Redacted.pdf&versionIdentifier=
Description
Redacted CSR Synopsis

Learn more about this trial

Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects

We'll reach out to this number within 24 hrs